Biopharma · FDA Approvals · Stock

PLUR Pluri

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO,…

Assets on file: regenerative medicine product portfolio

Start live analysis of PLUR Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for PLUR, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for PLUR, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 30, 2026

12:30 PM

PLURPluri Inc.

Pluri Grants ZEO Exclusive US License to Regenerative Medicine Portfolio

Pluri entered into a partnership agreement granting ZEO an exclusive license to manufacture and commercialize its regenerative medicine products in the US (with limited rights for aesthetics/skin care/cosmetic/veterinary uses). In exchange, Pluri receives 50% equity in ZEO plus warrants for additional equity, board nomination rights, and royalties.

Partnership / licensing dealSEC 8-K Open record